A Randomized, Blinded, Placebo-controlled Study to Assess Pharmacokinetics, Safety, and Tolerability of Ascending Doses of MEDI0382 in Non-diabetic Obese Subjects
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 08 Nov 2018
At a glance
- Drugs MEDI 0382 (Primary)
- Indications Obesity
- Focus Adverse reactions
- Sponsors MedImmune
- 02 Oct 2018 Status changed from recruiting to active, no longer recruiting.
- 05 Sep 2018 Planned End Date changed from 25 Dec 2018 to 11 Dec 2018.
- 05 Sep 2018 Planned primary completion date changed from 25 Dec 2018 to 11 Dec 2018.